ERIC BOERWINKLE to Pharmacogenomic Variants
This is a "connection" page, showing publications ERIC BOERWINKLE has written about Pharmacogenomic Variants.
Connection Strength
1.115
-
Genome-Wide Meta-Analysis of Blood Pressure Response to ?1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
Score: 0.148
-
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
Score: 0.135
-
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6).
Score: 0.134
-
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ?-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
Score: 0.134
-
Genetic Variants Associated With Uncontrolled Blood Pressure on?Thiazide Diuretic/?-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)?and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
Score: 0.131
-
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
Score: 0.123
-
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. J Med Genet. 2016 12; 53(12):835-845.
Score: 0.121
-
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens. 2016 09; 30(9):549-54.
Score: 0.116
-
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.
Score: 0.038
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
Score: 0.037